Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Livact exists in two forms: - **LIVACT Granules**: This is a branched-chain amino acid (BCAA) formulation containing L-isoleucine, L-leucine, and L-valine. It is developed by Ajinomoto Co., Inc. It is used to improve serum albumin levels in patients with liver disease, particularly those with decompensated hepatic cirrhosis and hypoalbuminemia despite adequate dietary intake. The mechanism of action involves correcting blood amino acid imbalances to induce albumin synthesis, potentially through the mTOR pathway. - **Livact Capsule**: This is a herbal medicine used to promote healthy liver function and remove toxins. It is manufactured by Sanjivani Parenteral Ltd. It contains a blend of herbs like *Andrographis paniculata* and *Phyllanthus niruri*. The exact mechanism is not fully understood, but it is believed to enhance liver function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Livact.